|
|
Post by bernstein on Sept 8, 2016 13:56:21 GMT
|
|
|
|
Post by CM kipper007 on Sept 13, 2016 15:53:23 GMT
Any news on this Bernstein? Hard for me to research today.
|
|
|
|
Post by CM kipper007 on Oct 12, 2016 21:51:08 GMT
|
|
|
|
Post by CM kipper007 on Nov 1, 2016 16:34:13 GMT
IntelGenX Corp. has added a new press release to its web site. For full details please visit the IntelGenX web site at: IntelGenx to Report Third Quarter 2016 Financial Results on November 10, 2016Click Here for a complete listing of IntelGenX press releases. INTELGENX TO REPORT THIRD QUARTER 2016 FINANCIAL RESULTS ON NOVEMBER 10, 2016 November 01, 2016 SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/01/16 -- IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its third quarter 2016 results for the period ended September 30, 2016, on November 10, 2016 at the close of the financial markets. An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below: Date: Thursday, November 10, 2016 Time: 4:30 p.m. EST Conference dial-in: (877) 201-0168 Conference ID: 97287160 International dial-in: (647) 788-4901 Webcast Registration: Click here Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations". About IntelGenx: IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release. Source: IntelGenx Technologies Corp. Edward Miller Director, IR and Corporate Communications IntelGenx Corp. +1 514-331-7440 (ext. 217) edward@intelgenx.com Source: IntelGenx Technologies Corp. |
|
|
|
Post by CM kipper007 on Nov 22, 2016 22:45:46 GMT
www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-Secures-a-License-For-Tadalafil-Erectile-Dysfunction-Dosing-Patent/default.aspxINTELGENX SECURES A LICENSE FOR TADALAFIL ERECTILE DYSFUNCTION DOSING PATENT November 21, 2016 SAINT LAURENT, QUEBEC -- (Marketwired) -- 11/21/16 -- IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today announced the signing of a binding term sheet for a license to Eli Lilly and Company's tadalafil dosing patent, United States Patent No. 6,943,166 (the '166 dosing patent). Any exclusivity associated with the tadalafil compound patent is not affected by this agreement. Subject to U.S. Food and Drug Administration (FDA) approval, this license allows IntelGenx to commercialize its Tadalafil ED VersaFilm™ product in the U.S. prior to the expiration of the '166 dosing patent. This license terminates all current tadalafil-related litigation activities for IntelGenx. IntelGenx will be actively seeking a partner for the commercialisation of the Tadalafil ED VersaFilm™ product. IntelGenx has developed a proprietary process and formulation for manufacturing the Tadalafil ED VersaFilm™ product and plans to manufacture the product for multiple markets around the world. IntelGenx plans to file Tadalafil VersaFilm™ 505(b)(2) NDA with the U.S. FDA in the second quarter of 2017 and expects a U.S. launch of the ED product upon approval, in the second quarter of 2018. "Securing the license with Lilly is a significant achievement for IntelGenx. It will substantially alleviate any legal concern regarding the launch of our Tadalafil VersaFilm™ product ahead of the expiry of the '166 dosing patent," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "This license opens IntelGenx to the lucrative U.S. ED market and accelerates our partnering of this product for commercialising Tadalafil VersaFilm™ in the U.S. and abroad. We look forward to continuing IntelGenx' transformation into a global leader of pharmaceutical oral films." IntelGenx was represented by H. Keeto Sabharwal and the law firm of Pillsbury Winthrop Shaw Pittman. About Tadalafil VersaFilm ™ Tadalafil is one of the three major PDE5 inhibitors in the ED market. Tadalafil shows longer duration of action and less food effect compared with the competitors ED product. IntelGenx's tadalafil film offers an improved discrete dosage form that does not require water intake. IntelGenx tadalafil film formulations have been tested in various clinical trials to improve the pharmacokinetics and optimize the formulation. The latest formulation successfully demonstrated bioequivalence to Cialis®(1) tablet in a pilot study. With the license in hand, IntelGenx may now target launch readiness ahead of Cialis® patent expiry. Tadalafil VersaFilm™ now has the potential to be the first generic competitor to the Cialis® tablet and the only film delivery product of the blockbuster ED drug product.
|
|
|
|
Post by CM kipper007 on Dec 1, 2016 17:46:20 GMT
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional ProductINTELGENX STRENGTHENS PARTNERSHIP WITH CHEMO GROUP BY SIGNING A CO-DEVELOPMENT TERM SHEET FOR AN ADDITIONAL PRODUCT December 01, 2016 SAINT-LAURENT, CANADA -- (Marketwired) -- 12/01/16 -- IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today strengthened its relationship with Chemo Group ("Chemo") by signing a term sheet for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. According to Global Data, worldwide sales in 2015 of the CNS related product exceeded $4 billion. Under the agreement, IntelGenx will receive an upfront payment, development costs of the product and future milestone payments. Chemo and IntelGenx will also share the profits of commercialization. "We are very pleased that we have further strengthened our relationship with Chemo," said Dr. Horst Zerbe, President and CEO of IntelGenx. "We are now collaborating with Chemo on a total of four products for future commercialization. The completion of a second transaction with Chemo, further validates our oral delivery platforms and our ability to attract high quality partners. We look forward to working with Chemo as our strategic partner in further expanding our global reach of our innovative pipeline." About Chemo Group: CHEMO operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Spain, Switzerland and Argentina, CHEMO is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. CHEMO's activity is organized in three synergistic business areas: Industrial, Branded and Biotech, with over 5,000 professionals in more than 40 countries, 20 state-of-the-art facilities, 9 specialized R&D centers, 12 commercial offices and more than 50 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. About IntelGenx: IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
|
|
|
|
Post by CM kipper007 on Dec 14, 2016 17:57:10 GMT
IntelGenx and RedHill Biopharma Announce Definitive Agreement for Commercialization of RIZAPORT(R) for Migraines with Pharmatronic Co. in South KoreaINTELGENX AND REDHILL BIOPHARMA ANNOUNCE DEFINITIVE AGREEMENT FOR COMMERCIALIZATION OF RIZAPORT(R) FOR MIGRAINES WITH PHARMATRONIC CO. IN SOUTH KOREA December 14, 2016 SAINT-LAURENT, CANADA -- (Marketwired) -- 12/14/16 -- IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), and RedHill Biopharma Ltd. (NASDAQ:RDHL)(TASE:RDHL), today announced the signing of an exclusive license agreement with Pharmatronic Co. ("Pharmatronic Co.") for the commercialization of RIZAPORT® in the Republic of Korea (South Korea). RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. Under the terms of the agreement, RedHill granted Pharmatronic Co. the exclusive rights to register and commercialize RIZAPORT® in South Korea. IntelGenx and RedHill are entitled to receive an upfront payment and will be eligible to receive additional milestone payments upon achievement of certain predefined regulatory and commercial targets, as well as tiered royalties. Further financial terms of the agreement were not disclosed. The initial term of the definitive agreement with Pharmatronic Co. is for ten years from the date of first commercial sale and shall automatically renew for an additional two-year term. Commercial launch in South Korea is estimated to take place in the first quarter of 2019. "We are most pleased to be entering the Asian market for the first time with Pharmatronic, a Korean organization committed to customer service excellence," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We will be working hard with our partners RedHill and Pharmatronic to bring our innovative product to market for patients in South Korea suffering with migraines. The execution of two commercialization agreements for RIZAPORT® in less than six months demonstrates our relentless execution of strategy to bring our innovative products to the global market." Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, said: "We are pleased to enter into our second commercialization agreement for RIZAPORT® and look forward to building a long-term relationship with Pharmatronic Co. This agreement for South Korea follows our recent commercialization agreement with Grupo JUSTE S.A.Q.F for Spain. We continue working diligently together with our partner IntelGenx to bring this unique migraine drug to additional markets and expect to re-submit the RIZAPORT® NDA to the FDA in the first half of 2017." RIZAPORT® (5 mg and 10 mg) was granted marketing authorization by the Federal Institute for Drugs and Medical Devices of Germany (BfArM) under the European Decentralized Procedure (DCP), in which Germany served as the Reference Member State for other European Union (EU) countries. This authorization was the first national marketing approval for RIZAPORT®. A first commercialization agreement was signed with Grupo JUSTE S.A.Q.F (Grupo JUSTE) for Spain and additional potential territories and, subsequently, a national Marketing Authorization Application (MAA) for RIZAPORT® was submitted by Grupo JUSTE in Spain under the European DCP. IntelGenx and RedHill expect to re-submit the RIZAPORT® New Drug Application (NDA) to the FDA in the first half of 2017 and subsequently receive a new PDUFA (Prescription Drug User Fee Act) date and are currently in discussions with potential commercialization partners for the U.S. market. About RIZAPORT ® (RHB-103): RIZAPORT® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. RIZAPORT® 5 mg and 10 mg were approved for marketing in Germany in October 2015 under the European Decentralized Procedure. A New Drug Application for RIZAPORT® was also filed with the U.S. FDA in 2013 and a CRL was received in 2014. RedHill has entered into licensing agreements to commercialize RIZAPORT® in Spain (with Grupo JUSTE S.A.Q.F) and in South Korea (with Pharmatronic Co.). Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. The worldwide annual sales of triptans were estimated to have exceeded $690 million in 2015(1). RIZAPORT® is based on IntelGenx's proprietary VersaFilm™ technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract. The administration method of the RIZAPORT® oral thin film, which does not require the patient to swallow a pill or consume water, along with its pleasant flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population(2) and patients suffering from dysphagia (difficulty swallowing). About RedHill Biopharma Ltd.: RedHill Biopharma Ltd. (NASDAQ:RDHL)(TASE:RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill's pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA™ (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. About Pharmatronic Co.: Pharmatronic Co. is a privately held pharmaceutical company headquartered in Seoul, South Korea which distributes exclusively licensed pharmaceutical products with innovative sales and marketing know-how. Since its establishment in 2005, Pharmatronic Co. has focused R&D and marketing resources on the specialized target field of neurology, ENT and urology, building a strong image as a leading provider in the pharmaceutical and healthcare industry. About IntelGenx: IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
|
|
|
|
Post by CM kipper007 on Dec 29, 2016 20:49:01 GMT
INTELGENX ANNOUNCES DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ENDO VENTURES December 27, 2016 SAINT-LAURENT, CANADA -- (Marketwired) -- 12/27/16 -- IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it has entered into a co-development and commercialization agreement with Endo Ventures Ltd. ("Endo") for a new product utilizing IntelGenx' proprietary VersaFilm™ for the USA market. Under the agreement, Endo has obtained certain exclusive rights to market and sell IntelGenx' product in the USA. IntelGenx will receive an upfront payment and future milestone payments. Endo and IntelGenx will share the profits of commercialization. "We are thrilled to further strengthen our partnership with such a significant global pharmaceutical organization as Endo," said Dr. Horst Zerbe, President and CEO of IntelGenx. "We see the completion of this deal as further validation of our VersaFilm™ technology and our ability to enter into high quality partnerships. IntelGenx continues to make tremendous progress in executing our strategy of becoming a global leader in pharmaceutical oral films." About IntelGenx: IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. |
|
|
|
Post by CM kipper007 on Jan 3, 2017 23:31:21 GMT
|
|
|
|
Post by CM kipper007 on Jan 4, 2017 17:41:21 GMT
Another announcement today:
INTELGENX ANNOUNCES DEFINITIVE AGREEMENT WITH CHEMO GROUP FOR A GENERIC CNS TABLET
January 04, 2017
SAINT-LAURENT, CANADA -- (Marketwired) -- 01/04/17 -- IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today announced the signing of a definitive agreement with Chemo Group ("Chemo") for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. According to Global Data, worldwide sales in 2015 of the CNS related product exceeded $4 billion. This definitive agreement signed December 30, 2016 follows the binding term sheet announced on December 1, 2016.
Under the agreement, IntelGenx is entitled to an upfront payment, development costs of the product and future milestone payments. Chemo and IntelGenx will also share the profits of commercialization.
"We are very pleased by the relentless execution of strategy in 2016 to successfully conclude seven transactions of our innovative products towards future commercialization," said Dr. Horst Zerbe, President and CEO of IntelGenx. "Four of those innovative products have been concluded with our strategic partner, Chemo, which clearly validates IntelGenx' advanced oral delivery platforms. We look forward to growing our relationship with Chemo in 2017 in further expanding the global reach of our innovative pipeline."
About Chemo Group:
CHEMO operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.
While the main offices are located in Spain, Switzerland and Argentina, CHEMO is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets.
CHEMO`s activity is organized in three synergistic business areas: Industrial, Branded and Biotech, with over 5,000 professionals in more than 40 countries, 20 state-of-the-art facilities, 9 specialized R&D centers, 12 commercial offices and more than 50 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
|
|
|
|
Post by CM kipper007 on Jan 6, 2017 17:54:13 GMT
|
|
|
|
Post by CM kipper007 on Jan 30, 2017 18:04:54 GMT
INTELGENX TO WEBCAST, LIVE, AT VIRTUALINVESTORCONFERENCES.COM FEBRUARY 2 January 30, 2017 Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com Saint-Laurent, Canada, January 30, 2017 /PRNewswire/ -- IntelGenx Technologies Corp. (OTCQX: IGXT), based in Montreal, focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmTM technology platform, today announced that Executive Vice President and CFO, Andre Godin will present live at VirtualInvestorConferences.com on February 2, 2017. DATE: Thursday, February 2, 2017 TIME: 1:45 p.m. EST LINK: tinyurl.com/201preprThis will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days. It is recommended that investors pre-register and run the online system check to save time and receive event updates. Learn more about the event at www.VirtualInvestorConferences.com. Recent Company Highlights In December 2016 IntelGenX signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) In December 2016 IntelGenx entered into a co-development and commercialization agreement with Endo for a new product utilizing IntelGenx' proprietary VersaFilm™ for the USA market In December 2016 IntelGenx signed an exclusive license agreement with Pharmatronic Co. for the commercialization of RIZAPORT® in the Republic of Korea (South Korea). RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines In November 2016 IntelGenx signed a binding term sheet for a license to Eli Lilly tadalafil erectile dysfunction dosing patent, United States Patent No. 6,943,166 (the '166 dosing patent) www.intelgenx.com/investors/press-releases/press-release-details/2017/IntelGenx-to-Webcast-Live-at--VirtualInvestorConferencescom-February-2/default.aspx |
|
|
|
Post by CM kipper007 on Feb 17, 2017 19:02:00 GMT
IntelGenx CEO speaks to the potential impact of Montelukast on Alzheimers
Mentions the Listerine strip they invented.
Talks about using the strip loading it with drugs as delivery system. Adds that it is easy to take for special needs people: kids, older people that may not be good with pills.
Also seems to be entering the cannabis market too.
|
|
|
|
Post by CM kipper007 on Feb 17, 2017 19:17:04 GMT
Is anyone else looking at this company? I know there was a couple of people looking at it. There just seems to be a lot of opportunity here... but not much noise... am I missing something?
|
|
|
|
Post by CM kipper007 on Mar 28, 2017 20:41:11 GMT
'boing!' Signed a binding term sheet with Eli Lilly for an exclusive license for tadalafil film products under erectile dysfunction (ED) dosing patent, United States Patent No. 6,943,166. www.intelgenx.com/investors/press-releases/press-release-details/2017/IntelGenx-Reports-Fourth-Quarter-and-Full-Year-2016-Financial-Results/default.aspxINTELGENX REPORTS FOURTH QUARTER AND FULL-YEAR 2016 FINANCIAL RESULTS March 28, 2017 SAINT LAURENT, QUEBEC -- (Marketwired) -- 03/28/17 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2016. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2016 Fourth Quarter Financial Highlights: Revenues reached $1.9 million, an increase of 27% over the same period last year Adjusted EBITDA was $635,000, compared to $429,000 over Q4-2015 Cash and cash equivalents and short-term investments totalled $4.5 million as at December 31, 2016 2016 Twelve-Month Financial Highlights: Revenue was $5.2 million, compared to $5.1 million over the same period last year Net comprehensive loss was $1.5 million, compared to net comprehensive income of $800,000 over the same period last year Adjusted EBITDA was negative $275,000, compared to positive $1.7 million in the same period last year Recent Operational Highlights: Signed a binding term sheet with Eli Lilly for an exclusive license for tadalafil film products under erectile dysfunction (ED) dosing patent, United States Patent No. 6,943,166. Signed a definitive agreement with Chemo Group for a generic CNS tablet Entered into a co-development and commercialization agreement with Endo Ventures for a new VersaFilm™ product Signed an exclusive license agreement with Pharmatronic Co. for the commercialization of RIZAPORT® in the Republic of Korea (South Korea) "We are very satisfied with our performance in 2016, a year marked by significant clinical and commercial progress," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "With a stronger management team in place and a clear strategy to accelerate our growth, we were able to complete a record seven new partnership transactions in 2016, significantly advancing our product pipeline towards commercialization. We are now focussing on delivering on these contracts and bringing the products to the market as expeditiously as possible, thus further establishing the Company's leadership position in pharmaceutical oral film development and manufacturing." Financial Results: Total revenues for the three-month period ended December 31, 2016 amounted to $1.9 million, representing an increase of $400,000, or 27%, compared to $1.5 million for the three-month period ended December 31, 2015. Total revenues for the twelve-month period ended December 31, 2016 amounted to $5.2 million, representing an increase of $100,000, or 2%, compared to $5.1 million for the twelve-month period ended December 31, 2015. The increase for the three-month period ended December 31, 2016 compared to the last year's corresponding period is mainly attributable to upfront payments received in Q4 2016. The increase for both the three-month periods ended December 31, 2016 compared to the previous year's corresponding periods was mainly attributable to upfront payments received throughout 2016. The mix of revenue components in 2016 continued to shift from royalties and milestones to deferred revenues from the monetization of Forfivo and upfront payments from multiple agreements signed in the period. Operating costs and expenses were $6.2 million for the full year 2016, versus $3.71 million for the corresponding 12-month period of 2015. For the twelve-month period of 2016, the Company had an operating loss of $981,000, compared to operating income of $1.4 million for the comparable period of 2015. Net comprehensive loss was $1.5 million, or $0.02 on a basic and diluted per share basis, for the twelve-month period of 2016, compared to net comprehensive income of $800,000, or $0.01 on a basic and diluted per share basis, for the comparable period of 2015. As at December 31, 2016, the Company's cash, cash equivalents and short-term investments totalled $4.5 million, compared with $2.9 million as at December 31, 2015. Annual Filings: The Company's annual report on Form 10-K and financial statements for the year ended December 31, 2016 as well as the 2017 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, Tuesday March 28, 2017 at 4:00 p.m. EDT. Conference Call Details: IntelGenx will host a conference call to discuss these 2016 fourth quarter and full year financial results today, Tuesday, March 28, 2017, at 4:30 p.m. EDT. The dial-in number for the conference call is (877) 201-0168 (Canada and United States) or (647) 788-4901 (International), conference ID 51039225. The call will be also be webcast live and archived for twelve months at www.intelgenx.com. About IntelGenx: IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. |
|
|
|
Post by JHam on Mar 30, 2017 8:38:31 GMT
Is anyone else looking at this company? I know there was a couple of people looking at it. There just seems to be a lot of opportunity here... but not much noise... am I missing something? IGXT is on my watchlist. I haven't pulled the trigger because I swore never to buy a penny/OCTC stock ever again, lol (which I know is silly). I do own shares in a company who they have a partnership with though. |
|
|
|
Post by CM kipper007 on Apr 5, 2017 21:08:18 GMT
|
|
|
|
Post by bernstein on Jun 2, 2017 14:08:21 GMT
Im back in this one because a lot of good news is on the way see below . Tadalafil a thin-film version of the blockbuster drug Cialis could enter the market up to2-3 years before the generics which is MEGA News for Intelgenx .US-NDA submission for Tadalafil expected 4-8 weeks and there is strong partner interest for the drug term sheet already received .I think now is a very good entry point .GL Market Cap :$46 Million Cash: Untill 2021+ (including convertible debt) Price: 0.72 www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-filmsIntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
transcript may 2017 s2.q4cdn.com/790425727/files/doc_financials/2017/Q1/final-051117-intelgenx-corp-q1-2017-financial-results-18899915.pdfNDA submission for tadalafil in June or July
NDA resubmission for Rizaport in July or August
Partnership for Tadalafil in 2H 2017
The trial with the ANDA applicants that submitted applications for generic copies, is scheduled for July. Some of the ANDA applicants have already settled with Lilly, settled in the sense that they have greed to launch their generic product only at the expiry of this third patent, the dosing patent that we obtained a license for. That means that we have a pretty good chance to enjoy an extended period of excessivity once we’ve launched our product. Several companies have expressed interest in licensing the product. Term sheets(phon)have been submitted and are currently being reviewed and the due-diligence process has commenced.
|
|
|
|
Post by bernstein on Jun 8, 2017 13:35:35 GMT
|
|
|
|
Post by bernstein on Jun 22, 2017 19:34:06 GMT
nice consolidation after the move in last days next leg up could drive it $1+
|
|
